Diarrhea News and Research

Latest Diarrhea News and Research

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

A team of international scientists recently conducted a randomized clinical trial to assess the safety and efficacy profiles of a novel probiotic formulation in symptomatic coronavirus disease 2019 (COVID-19) patients. The findings indicate that the probiotic formulation is highly effective in reducing symptom severity in COVID-19 patients without causing any adverse events.

25 May 2021

Campylobacter infection can also be spread through sexual contact

Campylobacter infection, one of the most common foodborne illnesses in the Western world, can also be spread through sexual contact, according to a new research discovery by an OU Hudson College of Public Health faculty member, working in conjunction with colleagues in Denmark.

21 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

Western diet impairs the gut immune system, could increase risk of inflammatory bowel disease

Eating a Western diet impairs the immune system in the gut in ways that could increase risk of infection and inflammatory bowel disease, according to a study from researchers at Washington University School of Medicine in St. Louis and Cleveland Clinic.

18 May 2021

New way to detect a diverse range of bacteria that cause diarrheal disease in informal settlements

Monash University researchers have validated a way to successfully detect a diverse range of bacteria (pathogens) that cause diarrheal disease in informal settlements.

17 May 2021

Huge healthcare burden of post-COVID-19 symptoms likely, suggests new study

How well do patients who had COVID-19 recover after the virus is cleared from their systems? A new preprint reports on symptom profiles over the first nine months of the illness.

13 May 2021

FDA approves higher dose naloxone hydrochloride nasal spray product to combat opioid overdose

The U.S. Food and Drug Administration announced today the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.

30 Apr 2021

"COVID-19 diarrhea" depends on inflammatory response that is part of the disease

Researchers in the United States have provided important insights into the pathophysiology of diarrhea that occurs in some cases of coronavirus disease 2019 (COVID-19).

29 Apr 2021

Fighting malaria in 2021: Where are we now and where are we going?

In support of World Malaria Day, News-Medical spoke to Dr. Laurence Slutsker, an internationally recognized expert in malaria, about fighting this disease in 2021.

26 Apr 2021

Real-world study in India finds COVISHIELD vaccine safe and effective

New research led by Naresh Trehan of Medanta-The Medicity in India found the COVISHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine) vaccine produced an immune response from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) two weeks after vaccination with limited side effects.

26 Apr 2021

COVID-19 survivors have increased risk of death for at least six months

As the COVID-19 pandemic has progressed, it has become clear that many survivors -; even those who had mild cases -; continue to manage a variety of health problems long after the initial infection should have resolved.

23 Apr 2021

FDA approves immunotherapy for treating patients with dMMR endometrial cancer

Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that affect the proper repair of DNA inside the cell), as determined by an FDA-approved test.

22 Apr 2021

Researchers aim to better understand clinical features associated with COVID-19 mortality

To better understand the COVID-19 clinical feaures associated with mortality, an interdisciplinary team of researchers has investigated important factors and their influence on a patient’s death.

22 Apr 2021

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.

19 Apr 2021

Candidate coronavirus vaccines show promising results in early animal testing

A candidate vaccine that could provide protection against the COVID-19 virus and other coronaviruses has shown promising results in early animal testing.

17 Apr 2021

FDA approves immunotherapy for first-line treatment of advanced gastric cancer

Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.

16 Apr 2021

Researchers identify risk factors for SARS-CoV-2 reinfection

A team of scientists from the Capital Medical University and Peking University, China, has recently explored the factors responsible for the reactivation of SARS-CoV-2 infection among individuals who have recently recovered from COVID-19. The findings reveal that individuals with lower lymphocyte count or with two or fewer symptoms during the first COVID-19 episode are at higher risk of recurrent infection.

16 Apr 2021

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Tapeworm infection drug blocks SARS-CoV-2 damage in the lungs

New research published in the journal Nature found the presence of SARS-CoV-2 in the lungs resulted in abnormal pneumocytes and spike protein-mediated cell fusion. Their findings also showed that TMEM16F protein activation induces cell fusion. Therefore, drugs inhibiting the TMEM16F/Anoctamin6 calcium-activated ion channel, such as niclosamide, could serve as potential treatments for reducing the severity of COVID-19 infection.

12 Apr 2021